What it is: A stabilized GHRH analog with FDA approval for reducing excess visceral belly fat in HIV patients on antiretroviral therapy - one of the few GH secretagogues with current FDA approval.
Research suggests: Multiple randomized controlled trials demonstrate significant visceral fat reduction; emerging research also suggests cognitive benefits in older adults through GH-related mechanisms.
Best for: Visceral fat reduction and GH optimization researchers
Key thing to know: The only GHRH analog with current FDA approval; its approval pathway provides a validated human safety and efficacy profile that most research peptides lack entirely.
What is Tesamorelin?
Tesamorelin is a stabilized synthetic analog of growth hormone-releasing hormone (GHRH), engineered with a trans-3-hexenoic acid modification at the N-terminus that extends its stability and half-life compared to native GHRH. It is FDA approved under the brand name Egrifta for the treatment of excess abdominal fat (lipodystrophy) in HIV-positive adults on antiretroviral therapy , a condition in which antiretroviral drugs cause abnormal fat accumulation around the visceral organs.
Among GH secretagogues studied in the research community, tesamorelin has one of the strongest clinical evidence bases, owing to the multiple Phase 3 randomized controlled trials required for its FDA approval. Researchers also study it for body composition improvement in non-HIV populations, metabolic health, and cognitive function in aging , an area where a subset of studies has generated notable findings.
How it works.
Tesamorelin stimulates the pituitary gland to release growth hormone through direct GHRH receptor activation. Its stabilized structure , the trans-3-hexenoic acid modification , protects it from rapid dipeptidyl peptidase IV (DPP-IV) degradation, allowing it to remain active longer than natural GHRH while still producing physiological GH pulses that respect the body's natural somatostatin-regulated feedback mechanisms.
The resulting GH elevation stimulates IGF-1 production in the liver and promotes lipolysis , the breakdown of stored triglycerides , particularly in visceral adipose tissue surrounding the abdominal organs. Visceral fat is metabolically active, secreting inflammatory cytokines and contributing to insulin resistance and cardiovascular risk. Research suggests tesamorelin preferentially reduces this metabolically harmful fat depot, with improvements in lipid profiles observed across multiple trials.
Think of it as directing the body's GH-driven fat metabolism specifically toward visceral fat , the fat that matters most from a cardiometabolic health perspective , while preserving the pulsatile, feedback-regulated nature of physiological GH secretion rather than producing the sustained supraphysiological GH levels associated with exogenous GH injections.
What the research shows.
Two pivotal Phase 3 randomized, double-blind, placebo-controlled trials , enrolling over 800 HIV-positive adults with abdominal lipodystrophy , formed the basis for FDA approval of Egrifta in 2010. Both trials demonstrated statistically significant reductions in visceral adipose tissue (VAT) measured by CT scan, alongside improvements in triglycerides and HDL cholesterol. These findings have been replicated in extension studies and additional independent trials.
Research has also examined tesamorelin in non-HIV populations. Studies in older adults and in individuals with mild cognitive impairment found improvements in cognitive function alongside the expected metabolic effects , adding a longevity dimension to its research profile that has generated growing interest in the aging medicine community. The cognitive findings are compelling but at a lower evidence tier than the visceral fat indication.
Biomarkers to review first.
IGF-1 monitoring is mandatory before and during any protocol involving tesamorelin. Additional metabolic and hormonal markers provide important context for assessing baseline and monitoring for expected GH-related changes.
What it's commonly researched with.
In research contexts, tesamorelin is most often studied alongside other GH secretagogues that target complementary steps in the GH axis, or alongside metabolic support compounds. These pairings represent what appears in the research literature , not recommendations for use.